Key Takeaways
- ARK Invest’s trading activity was limited to just three stock additions last week: Figma, Arcturus Therapeutics, and 10x Genomics
- The investment firm purchased 337,381 Figma shares totaling more than $8.1 million on March 20
- Circle Internet Group saw significant selling, with ARK offloading 45,998 shares worth approximately $5.9 million from ARKK and ARKW
- Despite delivering 40% quarterly revenue growth, Figma shares have plunged 83% from 2025 peak levels
- Additional sales included positions in Teradyne, Bullish, Guardant Health, and Butterfly Network
Cathie Wood’s ARK Invest displayed unusually restrained trading activity last week, making only three stock purchases amid a fourth consecutive week of market declines. All three major indexes posted losses during the period.
This minimal buying activity represents a departure from Wood’s usual strategy of increasing purchases during market downturns, catching the attention of market observers.
The investment firm concentrated its buying on three companies: Figma, Arcturus Therapeutics, and 10x Genomics. Simultaneously, ARK trimmed multiple positions, notably divesting shares of Circle Internet Group, a cryptocurrency-related company.
Figma operates as a cloud-based design platform serving website, application, and digital product development needs. On March 20, ARK accumulated 337,381 Figma shares through its ARKK and ARKW exchange-traded funds, investing $8,171,367.
Shares have plummeted 83% from their summer 2024 highs, following a rapid climb that saw the stock more than quadruple from its $33 IPO price. The significant decline occurred despite impressive fundamentals, with Figma delivering 40% revenue expansion in its latest quarterly report, accelerating from 38% in the prior period.
The company’s net dollar-retention rate reached 136%, indicating existing customers increased their platform spending by 36% year-over-year. This metric represents the strongest performance in this category over the past two years.
Wall Street analysts project revenue growth moderating to 30% for the current year and 20% for the following year. The absence of robust profitability has contributed to investor skepticism and stock weakness.
Cryptocurrency Exposure Trimmed Through Circle Internet Sale
In the digital asset space, ARK divested 45,998 shares of Circle Internet Group from its ARKK and ARKW funds, generating proceeds of $5,902,923. The sales represented a continuation of position reduction throughout the week.
Circle Internet operates within the cryptocurrency infrastructure sector, primarily recognized for its involvement with the USD Coin stablecoin platform.
Additional divestments included 19,206 Teradyne shares valued at $5,807,894, alongside 103,379 Bullish shares worth $4,093,808 and 9,621 Guardant Health shares totaling $857,038. ARK also liquidated 182,353 Butterfly Network shares for $723,941.
Life Sciences Focus: Arcturus and 10x Genomics Additions
Arcturus Therapeutics specializes in messenger RNA-based therapeutic development targeting rare respiratory and hepatic conditions. ARK accumulated Arcturus shares on three separate trading sessions last week, concluding with a 22,773-share purchase on Friday worth $153,034 through its ARKG fund.
The company has experienced three consecutive years of revenue contraction, with forecasts projecting additional declines through 2026. Positively, Arcturus recently secured funding extending its operational runway through at least Q2 2028.
10x Genomics produces life sciences research tools, highlighted by its Chromium platform designed for single-cell genomic analysis. Last week, ARK acquired 192,658 shares across ARKK and ARKG portfolios, investing $3,541,054.
The stock currently trades at approximately half its $38 IPO price. The company has yet to achieve profitability, and management’s 2026 revenue guidance suggests potential contraction when excluding one-time licensing income from previous patent settlement agreements.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
